Gangliosides and Neurotrophic Factors in Neurodegenerative Diseases: From Experimental Findings to Clinical Perspectives
- 1 September 1993
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 695 (1) , 314-317
- https://doi.org/10.1111/j.1749-6632.1993.tb23074.x
Abstract
A large body of experimental data suggests that neurotrophic molecules and/or substances that facilitate their action could be pharmaceutical agents for neurodegenerative pathologies. In particular, it has been demonstrated that nerve growth factor (NGF) exerts a physiological role for forebrain cholinergic neurons, while brain-derived neurotrophic factor (BDNF) seems to play a relevant role in rescuing dopaminergic neurons following damage. In addition, gangliosides are reported to potentiate neurotrophic factor effects in vitro as well as in vivo. In this study we examined the effects of the monosialoganglioside GM1 in different experimental models. The responsiveness of forebrain cholinergic neurons following NGF +/- GM1 was evaluated by assessing choline acetyltransferase (ChAT) activity in hippocampus, septal area and striatum of behaviorally impaired 24-month-old rats. NGF was intracerebroventricularly (i.c.v.) infused for 2 weeks while GM1 was given systemically for 3 weeks, starting from the beginning of NGF infusion. Moreover, the possible protective effects of GM1 were assessed following exposure of cultured cerebellar granule cells and dopaminergic mesencephalic neurons to different doses of 6-OH-DOPA, a metabolite of the dopamine pathway which has excitotoxic properties and has been hypothesized to participate in the pathology of Parkinson's disease. GM1 treatment to aged rats was seen to potentiate the NGF-induced increase of ChAT activity in the striatum ipsilateral to the NGF infusion. Moreover, in the striatum contralateral to the NGF infusion, GM1 increased ChAT activity above the control values, whereas NGF treatment alone did not affect enzymatic activity. GM1 treatment of cerebellar granule cells and mesencephalic neurons counteracted the dose- and time-dependent neurotoxicity of 6-OH-DOPA. These data support the notion that GM1 might prove useful in treating those pathological conditions where trophic factor deficits and/or excitotoxin-related toxicity play an important role.Keywords
This publication has 14 references indexed in Scilit:
- Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione SystemJournal of Neurochemistry, 1992
- BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigraNature, 1991
- Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.Proceedings of the National Academy of Sciences, 1991
- Excitatory amino acid neurotoxicity and neurodegenerative diseaseTrends in Pharmacological Sciences, 1990
- Evidence for a physiological role of nerve growth factor in the central nervous system of neonatal ratsNeuron, 1989
- Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons.Proceedings of the National Academy of Sciences, 1989
- Nerve growth factor affects uninjured, adult rat septohippocampal cholinergic neuronsNeuroscience, 1989
- GM1 ganglioside potentiates the effect of nerve growth factor in preventing vinblastine-induced sympathectomy in newborn ratsBrain Research, 1988
- NGF-Mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: Evidence for a physiological role of NGF in the brain?Developmental Brain Research, 1983
- A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer diseaseAnnals of Neurology, 1981